Ubs Group Ag Icosavax, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$5.95 - $15.79 $1.44 Million - $3.83 Million	242,325 Added 1666.15%	256,869 $4.05 Million
Q3 2023 Nov 09, 2023	BUY	$7.22 - $10.05 $51,861 - $72,189	7,183 Added 97.58%	14,544 $112,000
Q2 2023 Aug 11, 2023	BUY	$4.89 - $10.57 $33,310 - $72,002	6,812 Added 1240.8%	7,361 $73,000
Q1 2023 May 12, 2023	SELL	$5.62 - $11.51 $14,325 - $29,338	-2,549 Reduced 82.28%	549 $3,000
Q4 2022 Feb 08, 2023	SELL	$2.32 - $10.97 $399,067 - $1.89 Million	-172,012 Reduced 98.23%	3,098 $24,000
Q3 2022 Nov 10, 2022	SELL	$3.09 - $9.21 $47,518 - $141,631	-15,378 Reduced 8.07%	175,110 $553,000
Q2 2022 Aug 10, 2022	BUY	$5.7 - $10.33 $1.09 Million - $1.97 Million	190,488 New	190,488 $1.09 Million

1.37M

Ticker ICVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,885,200
Description
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical tri...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.